ARPI (ANDROGEN RECEPTOR PATHWAY INHIBITORS) IN THE TREATMENT OF METASTATIC PROSTATE CARCINOMA, RESULTS FROM ONE SITE
Abstract
The authors evaluated the results of treatment with individual preparations in patients with metastatic hormone-sensitive (mHSPC) and castration-resistant (mCRPC) prostate cancer.